Skip to main content
. 2015 Sep;36(9):2458–2467. doi: 10.1016/j.neurobiolaging.2015.05.015

Table 1.

Demographic, clinical, and cognitive measures

Demographic, clinical, and cognitive measures DLB (n = 18) AD (n = 19) HC (n = 17) p-value
Male:female 13:5 16:3 14:3 χ2 = 0.93, p = 0.62a
Age 77.2 ± 6.18 74.7 ± 8.5 76.8 ± 5.7 F2,51 = 0.671, p = 0.516b
MMSE 23.6 ± 3.9 22.58 ± 2.9 29.1 ± 0.85 t35 = 0.91, p = 0.36c
UPDRS 17.44 ± 7.8 1.74 ± 1.8 1.41 ± 1.87 t34 = 0.53, p = 0.59d
CAMCOG 76.2 ± 13.5 72.2 ± 11.5 96.4 ± 3.37 t35 = 0.97, p = 0.33c
CAF scale 3.29 ± 4.06e 0.61 ± 1.54f na t33 = 2.61, p = 0.006c
NPI total 8.71 ± 5.47e 6.33 ± 7.07f na t33 = 1.10, p = 0.277c
NPI hallucinations 1.65 ± 1.83e 0.0 ± 0.0f na t33 = 3.81, p < 0.001c

Values expressed as mean ± 1 standard deviation.

Key: AD, Alzheimer's disease; CAF, Clinical Assessment of Fluctuating Confusion; CAMCOG, Cambridge Cognitive Examination; DLB, dementia with Lewy bodies; HC, healthy controls; MMSE, Mini-Mental State Examination; na, not applicable; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson's Disease Rating Scale.

a

χ2 test, DLB, AD, and HC.

b

Analysis of variance DLB, AD, and HC.

c

Student t test AD and DLB.

d

Student t test HC and AD.

e

(n = 17).

f

(n = 18).